Pluristem Therapeutics Given New $3.00 Price Target at Jefferies Group (PSTI)

Share on StockTwits

Pluristem Therapeutics (NASDAQ: PSTI) had its target price decreased by Jefferies Group from $3.50 to $3.00 in a research note released on Wednesday morning, StockRatingsNetwork.com reports. They currently have a hold rating on the stock.

“On 6/4/13, PSTI announced FDA has placed its Phase 2 for lead stem-cell product candidate PLX-PAD on clinical hold in light of a single episode of serious allergic reaction, creating further uncertainty regarding the timing of Phase 3 initiation (by ~YE13 previously). FDA will issue formal letter with questions and requests for information within the next month.,” the firm’s analyst wrote.

Shares of Pluristem Therapeutics (NASDAQ: PSTI) traded down 1.00% during mid-day trading on Wednesday, hitting $2.96. Pluristem Therapeutics has a one year low of $2.26 and a one year high of $5.00. The stock’s 50-day moving average is currently $3.09. The company’s market cap is $173.6 million.

A number of other firms have also recently commented on PSTI. Analysts at Maxim Group downgraded shares of Pluristem Therapeutics from a buy rating to a hold rating in a research note to investors on Tuesday. Analysts at MLV Capital initiated coverage on shares of Pluristem Therapeutics in a research note to investors on Friday, May 31st. They set a buy rating and a $4.50 price target on the stock.

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Latest News

Allergen Bid Might Be Better for Teva
Allergen Bid Might Be Better for Teva
Biogen Slashes Forecast on Weakness of Tecfidera
Biogen Slashes Forecast on Weakness of Tecfidera
Whirlpool Profit for the Quarter Drops on Strong Dollar
Whirlpool Profit for the Quarter Drops on Strong Dollar
Morgan Stanley Revenue Helps It Beat the Street
Morgan Stanley Revenue Helps It Beat the Street
Hertz Projecting Earnings at Top of Forecasted Range
Hertz Projecting Earnings at Top of Forecasted Range
Earnings at Goldman Sachs Tumble
Earnings at Goldman Sachs Tumble


Advertisement
Advertisement
© 2006-2015 Ticker Report. Google+.